Li Zhang
Led the Chinese trials of PD-1 blockade in nasopharyngeal and lung cancer and the early studies of the EGFR×HER3 bispecific ADC iza-bren.
Li Zhang runs medical oncology at SYSUCC and has been principal investigator on camrelizumab and toripalimab lung and nasopharyngeal trials and on early-phase studies of izalontamab brengitecan (BL-B01D1) in NSCLC and nasopharyngeal carcinoma.
Pages like this
not linked directly; found by shared links- PersonWenfeng Fang
Shares Camrelizumab, Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- TrialJUPITER-02
Shares Toripalimab, Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
- PersonRui-Hua Xu
Shares Toripalimab, Camrelizumab, Sun Yat-sen University Cancer Center.
- IdeaTwo-target antibody drugs to close the antigen escape route
Shares SystImmune / Sichuan Biokin, Izalontamab brengitecan.
- PersonMu-Sheng Zeng
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
- IdeaBlood EBV DNA screening for nasopharyngeal cancer across southern China and Southeast Asia
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
- PersonJun Ma
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
- CollectionCSCO guidelines (China)
Shares Toripalimab, Camrelizumab, Sun Yat-sen University Cancer Center.